COR

Based on Cencora, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Cencora do?

Cencora sources and distributes pharmaceutical products — including generics, specialty drugs, vaccines, and over-the-counter items — to hospitals, retail pharmacies, clinics, and long-term care facilities. It also provides pharmacy consulting, clinical trial support, and veterinary pharmaceutical products through its international and domestic segments.

Does COR pay dividends?

Yes, Cencora pays a regular dividend. This is consistent with its profile as a mature, cash-flow-generating pharmaceutical distributor. Investors should review the full financial profile — including the Risk pillar rating — before drawing conclusions about dividend sustainability.

When does COR report earnings?

Cencora reports on a quarterly cadence, as is standard for US-listed large-cap companies. For exact upcoming reporting dates and the most recent quarterly results, check Cencora's investor relations page directly.

Is COR a good stock to buy?

UQS Score rates COR as Below Average overall. The Valuation pillar is rated Good, but the Risk pillar is rated Weak, and Quality, Moat, and Growth are all Neutral. Whether that profile suits your portfolio depends on your risk tolerance and investment goals. The full pillar breakdown is available to Pro members.

Is COR overvalued?

The UQS Valuation pillar for COR is rated Good, suggesting the stock is not trading at an extreme premium relative to its fundamentals. However, valuation alone does not determine investment quality — the Weak Risk rating and Neutral growth profile are also relevant context.

How does COR compare to its competitors?

Cencora operates alongside Cardinal Health and McKesson in the highly concentrated US pharmaceutical distribution market. McKesson is the largest by scale, while Cardinal Health has a broader product manufacturing presence. Cencora differentiates through specialty pharmaceutical distribution and its international segment. UQS Score comparisons across these tickers are available on each company's page.

What is COR's market cap bracket?

Cencora is classified as a large-cap company, reflecting its significant scale as one of the leading pharmaceutical distributors in the United States and internationally.

Who founded Cencora?

Cencora was founded in 1995. The company was originally known as AmeriSourceBergen before rebranding to Cencora in 2023. Founding and corporate history details are widely available through public sources and the company's own investor relations materials.

Is COR a long-term quality investment?

As a long-term quality indicator, COR's UQS Score of Below Average reflects a business with stable but undifferentiated characteristics. The Neutral Moat rating suggests limited structural advantages that would protect returns over time, while the Weak Risk pillar introduces uncertainty. Long-term investors should weigh these factors carefully using the full Pro analysis.

What is the main competitive advantage of Cencora?

Cencora's scale in pharmaceutical distribution — particularly in specialty drugs and oncology — provides some operational leverage. However, the UQS Moat pillar is rated Neutral, indicating that these advantages are not yet translating into a clearly differentiated competitive position relative to sector peers.

What sector does COR belong to?

Cencora operates in the Healthcare sector, specifically within pharmaceutical distribution and related services. It serves a wide range of healthcare customers including hospitals, retail pharmacies, clinics, and animal health markets across the US and internationally.

Cencora, Inc. has average quality metrics, with room for improvement in margins or capital efficiency.

Cencora, Inc. shows steady but unspectacular growth, typical for mature companies.

Cencora, Inc. presents elevated risk with concerns around leverage or financial stability.

Cencora, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.

Cencora, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for COR.

The UQS (Unified Quality Score) for Cencora, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Cencora, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Cencora, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.